3,5-Dichloro-4-(3-bromo-4-isobutyramidophenoxy)phenylacetic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-Dichloro-4-(3-bromo-4-isobutyramidophenoxy)phenylacetic acid
• 英文别名: 2-[4-[3-bromo-4-(2-methylpropanoylamino)phenoxy]-3,5-dichlorophenyl]acetic acid
• 化学式: C₁₈H₁₆BrCl₂NO₄
• 分子量: 461.139
• InChiKey: HHSRCUBLBZYJPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,5-Dichloro-4-(3-bromo-4-isobutyramidophenoxy)phenylacetic acid 、 盐酸肌氨酸 、 methyl N-[3,5-dichloro-4-(3-bromo-4-isobutyramidophenoxy)phenylacetyl]-glycine 以to give 14 mg (22%) of N-[3,5-dichloro-4-(3-bromo-4-isobutyramidophenoxy)phenylacetyl]glycine, m/z 518的产率得到N-[3,5-dichloro-4-(3-bromo-4-isobutyramidophenoxy)phenylacetyl]glycine
  参考文献：
  名称：

  Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones

  摘要：

  本发明涉及公式（I）化合物，其是甲状腺受体配体，且最好具有选择性地结合甲状腺激素受体β，涉及制备这种化合物的方法以及使用这种化合物的方法，例如在代谢调节中的使用。

  公开号：

  US07199265B2
• 作为产物：
  描述：

  2-[3,5-Dichloro-4-(4-nitrophenoxy)phenyl]acetic acid 在 platinum(IV) oxide sodium hydroxide 、 氯化亚砜 、 TEA 、 四溴环己二烯-1-酮 、 氢气 作用下， 以 甲醇 、 二氯甲烷 为溶剂， -30.0~20.0 ℃ 、202.65 kPa 条件下， 生成 3,5-Dichloro-4-(3-bromo-4-isobutyramidophenoxy)phenylacetic acid
  参考文献：
  名称：

  Thyroid receptor ligands. Part 4: 4′-amido bioisosteric ligands selective for the thyroid hormone receptor beta

  摘要：

  Based on the examination of the X-ray crystallographic structures of the LBD of TR alpha and TR beta in complex with KB-141 (2), a number of novel 4'-hydroxy bioisosteric thyromimetics were prepared. Optimal affinity and P-selectivity (33 times), was found with a medium-sized alkyl-substituted amido group; iso-butyl (12c). It can be concluded that bioisosteric replacements of the 4'-hydroxy position represent a new promising class of TR beta-selective synthetic thyromimetics. (c) 2005 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2005.11.002

文献信息

• THYROID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF DISORDERS INFLUENCED BY THYROID HORMONES
  申请人：KARO BIO AB

  公开号：EP1296936A1

  公开（公告）日：2003-04-02
• US7199265B2
  申请人：——

  公开号：US7199265B2

  公开（公告）日：2007-04-03
• [EN] THYROID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF DISORDERS INFLUENCED BY THYROID HORMONES<br/>[FR] LIGANDS DE RECEPTEUR THYROIDIEN, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES DUS AUX HORMONES THYROIDIENNES
  申请人：KAROBIO AB

  公开号：WO2001098256A1

  公开（公告）日：2001-12-27

  This invention relates to compounds of the formula (I) which are thyroid receptor ligands, and are preferably selective for the thyroid hormone receptor β, to methods of preparing such compounds and to methods for using such compounds such as in the regulation of metabolism.
• Thyroid receptor ligands. Part 4: 4′-amido bioisosteric ligands selective for the thyroid hormone receptor beta
  作者：Yi-Lin Li、Chris Litten、Konrad F. Koehler、Karin Mellström、Neeraj Garg、Ana Maria Garcia Collazo、Mathias Färnegård、Marlena Grynfarb、Bolette Husman、Johnny Sandberg、Johan Malm

  DOI：10.1016/j.bmcl.2005.11.002

  日期：2006.2

  Based on the examination of the X-ray crystallographic structures of the LBD of TR alpha and TR beta in complex with KB-141 (2), a number of novel 4'-hydroxy bioisosteric thyromimetics were prepared. Optimal affinity and P-selectivity (33 times), was found with a medium-sized alkyl-substituted amido group; iso-butyl (12c). It can be concluded that bioisosteric replacements of the 4'-hydroxy position represent a new promising class of TR beta-selective synthetic thyromimetics. (c) 2005 Published by Elsevier Ltd.
• Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones
  申请人：——

  公开号：US20040097589A1

  公开（公告）日：2004-05-20

  This invention relates to compounds of the formula (I) which are thyroid receptor ligands, and are preferably selective for the thyroid hormone receptor &bgr;, to methods of preparing such compounds and to methods for using such compounds such as in the regulation of metabolism. 1

  这项发明涉及到公式(I)的化合物，这些化合物是甲状腺受体配体，且最好是选择性作用于甲状腺激素受体β，涉及到制备这类化合物的方法以及利用这类化合物的方法，如在代谢调节中的应用。